Compare Ascendis Pharma A/S (ASND) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Ferrari NV — how do they compare? Ascendis Pharma A/S trades at $260.65 (market cap $16.67B), while Ferrari NV trades at $409.9 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 4.3× Ascendis Pharma A/S's market cap, and Ferrari NV pays a 1.04% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | RACE | |
|---|---|---|
Market Cap | $16.67B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $504.09 |
52-Week Low | $189.74 | $314.63 |
Enterprise Value | $17.04B | $73.60B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Ferrari (RACE) trades at $407.21, up 0.11% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, with 2025 revenue at $7.15 billion and net income margin of 22.25%, though valuation multiples like P/E of 37.93 are elevated.
The outlook remains positive given earnings beats, raised guidance, and analyst consensus favoring buys, but risks include high valuation sensitivity and economic cyclicality. Upside to the $462.67 price target depends on sustained premium demand execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
